Rebecca Tech Secures Tens of Millions in Series A++ Funding to Advance Multi-Product Platform Based on Micro-RF Technology

VCBeat has learned that, recently,A Leading Domestic Manufacturer of MEMS RF TechnologyRebeccatech Medical(Rebecca Tech, hereinafter referred to as “Rebeccatech”)Announced the completion of a multi-million dollar A++ round of financing.This round of financing was led byMed-Fine Health FundLead Investor,PwCLeadingCo-investment,Dianshi CapitalContinuing to serve as the exclusive financial advisor. The funds raised in this round will be primarily used to promote the international exclusive micro-radiofrequency product line for general practice and to obtain registration and certification for new products in the Middle East, the Americas, and Europe.

Rebeccatech specializes in the development of biocompatible micro-electro-mechanical systems (MEMS) technology, dedicated to promoting its clinical applications in urology, dermatology, hepatology, and other fields. Founded by a core MEMS technology team from California, USA, the company has secured hundreds of millions of RMB in venture capital from both domestic and international sources, as well as tens of millions of USD in R&D project support. After winning the championship in the Digital Health category at DEMO CHINA 2017, it received angel investment from ZhenFund, founded by Mr. Xu Xiaoping, and subsequently attracted continuous funding from leading professional institutions such as Med-Fine Capital, Qifu Capital, and Hillhouse Ventures. Starting from the A+ round, Professor Li Zexiang, known as the “Godfather of DJI,” and Professor Gao Bingqiang, a world-renowned microelectronics expert, have supported the company’s growth as mentors and shareholders.

Group Photo of the Rebeccatech Medical Team

In clinical treatment scenarios, the development of "non-silicon-based" technologies is an inevitable trend: on one hand, the silicon chip industry is a highly constrained sector subject to significant bottlenecks, with silicon processing techniques facing numerous restrictions; on the other hand, silicon exhibits poor biocompatibility, and many fabrication processes used in silicon-based microelectromechanical systems (MEMS) involve biological toxicity, precluding their application in internal human disease treatments.

Modern non-silicon-based manufacturing technologies not only achieve the precision of traditional silicon-based processing but also utilize fully biocompatible materials, thereby overcoming the traditional reliance on silicon substrates in micro- and nanoscale design and fabrication. Specifically, by fully leveraging organic and flexible materials along with novel processing techniques, and by maximizing the volume and cost advantages of high-end electronic packaging integration production lines, these technologies make the widespread adoption of micro- and nanotechnologies in medical and electronic products possible.

Founder Dr. Zhang Yang tests his OAB micro-radiofrequency therapy device, whose product design facilitates the rapid widespread adoption of the treatment.

Micro-radiofrequency technology has demonstrated favorable clinical outcomes in the treatment of overactive bladder (OAB). Data indicate that the overall prevalence of OAB in China is 16.6%, increasing with age, with more than 3 million patients suffering from severe cases. The U.S. Food and Drug Administration (FDA) has also reported that over 33 million Americans are affected by OAB, including more than 1 million with severe symptoms.

Rebeccatech’s OAB micro-radiofrequency therapy device delivers radiofrequency ablation to the nerves at the bladder neck via a disposable catheter integrated with a micro-radiofrequency unit, thereby reducing neural sensitivity. Approved in 2020, it is the only approved micro-radiofrequency therapy for overactive bladder (OAB) in China and the world’s first such product launched globally.

Based on existing clinical data, the product achieves a 74% improvement rate in OAB symptoms, with significant reductions in urinary frequency, urgency, and nocturia. It holds a commanding global lead in both the number of treated cases and treatment success rates. Furthermore, as this procedure does not require cystoscopy, it significantly shortens the learning curve, facilitating rapid adoption in primary care hospitals and thereby benefiting hundreds of millions of OAB patients worldwide.

Rebeccatech’s other blockbuster product, the Laipu NEBULYFT micro-radiofrequency beauty device, completed the U.S. National Science Foundation I-Corps program in 2020 and successfully concluded its crowdfunding campaign in the United States.The product is developed based on the company’s intelligent micro-radiofrequency technology platform. Its entire production process adheres to standards certified by drug regulatory authorities. It has obtained professional certifications from CE and FDA, and has won multiple international awards.

In 2023, Lapu NEBULYFT, as the only Chinese beauty device brand to support the Cannes Film Festival, launched a co-branded product with Chopard. By the end of last year, global shipments of its beauty devices had surpassed 10,000 units. Meanwhile, the company has actively responded to the implementation of policies and enforcement of standards issued by the National Medical Products Administration (NMPA) for radiofrequency beauty devices, with its series of products currently undergoing registration as Class III medical devices.

NEBULYFT Attends the Cannes Film Festival

For this round of financing,Dr. Zhang Yang, Founder of RebeccatechHe stated, “We extend our heartfelt gratitude to both new and existing shareholders for their strong support, which has injected powerful strategic momentum into the cause of human health. Against the backdrop of increasingly fierce competition in the global medical device market, continuous technological innovation and market acumen are key to corporate survival and development. We will remain true to our original aspiration of putting people first, dedicating ourselves wholeheartedly, and embracing agile trial-and-error approaches, while deeply developing cutting-edge clinical applications of micro-electromechanical systems (MEMS) technology. On the market front, the company will strive to expand its presence in Greater China, the Middle East, and Europe and America, aiming to deliver satisfactory results to shareholders within two years and further advance truly original, non-substitutive medical technologies.”

Teacher Gao Bingqiang“Rebeccatech is the first company I have invested in that has gained market recognition for its application of MEMS chips in medical settings. The founding team possesses extensive experience in the international development of micro-electromechanical products, and their solutions have demonstrated significant clinical efficacy in core hospitals across Hong Kong and mainland China. I am also personally fond of using Rebeccatech’s personal care products, which are safe and effective!”

Zhou Yujian, Managing Partner of Med-Fine Capitalstated: “Rebeccatech, leveraging its high-barrier non-silicon-based MEMS technology, has overcome technical bottlenecks hindering industry development and expanded the indications for radiofrequency (RF) therapy. Its micro-RF therapeutic device for urology has received the world’s first regulatory approval, creating opportunities to improve the quality of life for patients with refractory overactive bladder (OAB). The company’s home-use RF aesthetic device has achieved revolutionary improvements in both functionality and safety; amid increasingly stringent national regulations on RF-based medical aesthetic products, it remains fully compliant and holds broad future prospects. With a highly executable team committed to continuous innovation, Rebeccatech is steadily expanding the application of its non-silicon-based MEMS technology across other clinical fields. We are very optimistic about the development prospects of the company’s technology platform and are honored to lead this round of financing.”

Yang Wenlei, Senior Vice President of Dianshi Capital“Congratulations to Rebeccatech on completing this round of financing! This marks the first collaboration between the Dianshi team and Rebeccatech, and we are honored to have witnessed the company’s growth through the pandemic. The Rebeccatech team boasts extensive experience in industry-academia-research integration within the field of radiofrequency micro-electromechanical systems (RF MEMS). The company’s internationally pioneering product for overactive bladder (OAB) treatment has been adopted by numerous Grade A tertiary hospitals across China, fully demonstrating its technical strength. Additionally, the NEBULYFT beauty device has received unanimous acclaim from users like ourselves.”

Med-Fine Health Fund focuses on investments in the pharmaceutical, healthcare, and life sciences sectors, with offices in Shanghai, Beijing, and Shenzhen. The management team boasts a broad international perspective, deep industry background, extensive industry resources, and professional investment expertise. Currently, the firm manages four RMB-denominated funds and two USD-denominated funds. The fund emphasizes “early-stage value discovery and sector opportunity identification,” focusing on investment opportunities in biopharmaceuticals, medical devices and diagnostics, digital health, and health technology. Guided by the vision of “Mapping the Horizon of Life and Health” and the mission to “Leverage Capital to Foster Innovative Development in the Healthcare Industry,” Med-Fine upholds the values of “Customer First, Talent Excellence, Quality Leadership, and Rewarding Trust.” By integrating “decentralized investment” with “systematic operations,” Med-Fine is committed to becoming an open, platform-based, highly competitive, and widely renowned international professional investment institution.

Dianshi Capital is a boutique investment bank with a composite profile, focusing on the life sciences and materials science sectors and backed by strategic consulting, investment and financing, and industrial expertise. We position ourselves as the “Strategic Development Department” and comprehensive external brain for growth-stage life sciences and materials science enterprises, serving as a trusted capital partner to achieve multi-party win-win outcomes for investors, entrepreneurs, and Dianshi Capital.